IL92622A - Pharmaceutical composition containing an inhibitor of the enzymatic conversion of protoporphyrinogen to protoporphyrin ix for use in the treatment or detection of tumors - Google Patents

Pharmaceutical composition containing an inhibitor of the enzymatic conversion of protoporphyrinogen to protoporphyrin ix for use in the treatment or detection of tumors

Info

Publication number
IL92622A
IL92622A IL9262289A IL9262289A IL92622A IL 92622 A IL92622 A IL 92622A IL 9262289 A IL9262289 A IL 9262289A IL 9262289 A IL9262289 A IL 9262289A IL 92622 A IL92622 A IL 92622A
Authority
IL
Israel
Prior art keywords
aryl
compound
protoporphyrinogen
protoporphyrin
composition
Prior art date
Application number
IL9262289A
Other languages
English (en)
Other versions
IL92622A0 (en
Inventor
Blaik Phillip Halling
Debra Ann Witkowski
Original Assignee
Fmc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Corp filed Critical Fmc Corp
Publication of IL92622A0 publication Critical patent/IL92622A0/xx
Publication of IL92622A publication Critical patent/IL92622A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL9262289A 1988-12-12 1989-12-10 Pharmaceutical composition containing an inhibitor of the enzymatic conversion of protoporphyrinogen to protoporphyrin ix for use in the treatment or detection of tumors IL92622A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28515188A 1988-12-12 1988-12-12
US33500789A 1989-04-07 1989-04-07
US35133189A 1989-05-03 1989-05-03

Publications (2)

Publication Number Publication Date
IL92622A0 IL92622A0 (en) 1990-08-31
IL92622A true IL92622A (en) 1996-05-14

Family

ID=27403508

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9262289A IL92622A (en) 1988-12-12 1989-12-10 Pharmaceutical composition containing an inhibitor of the enzymatic conversion of protoporphyrinogen to protoporphyrin ix for use in the treatment or detection of tumors

Country Status (28)

Country Link
EP (1) EP0447491B1 (enExample)
JP (1) JP2545000B2 (enExample)
KR (1) KR930003116B1 (enExample)
AR (1) AR243605A1 (enExample)
AT (1) AT400520B (enExample)
AU (1) AU633537B2 (enExample)
BR (1) BR8907817A (enExample)
CA (1) CA2004979A1 (enExample)
CH (1) CH681779A5 (enExample)
DE (2) DE3991484T (enExample)
DK (1) DK110791A (enExample)
EG (1) EG18822A (enExample)
ES (1) ES2051675T3 (enExample)
FI (1) FI912784A0 (enExample)
GB (1) GB2247404B (enExample)
GR (1) GR1000609B (enExample)
HU (1) HUT58202A (enExample)
IE (1) IE62621B1 (enExample)
IL (1) IL92622A (enExample)
LU (1) LU87949A1 (enExample)
LV (1) LV10303B (enExample)
MC (1) MC2171A1 (enExample)
NO (1) NO912228L (enExample)
NZ (1) NZ231658A (enExample)
OA (1) OA09362A (enExample)
PT (1) PT92546B (enExample)
SE (1) SE505938C2 (enExample)
WO (1) WO1990006748A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298502A (en) * 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
US5132101A (en) * 1990-05-04 1992-07-21 Cytopharm, Inc. Acetylene-cumulene porphycene compounds for photodynamic therapy
US5244671A (en) * 1991-01-29 1993-09-14 Cytopharm, Inc. Derivatives of porphycene for photodynamic therapy of cancer
US5179120A (en) * 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
GB9318841D0 (en) * 1993-09-10 1993-10-27 Res Foundation Of The Norwegia Composition
US5767373A (en) 1994-06-16 1998-06-16 Novartis Finance Corporation Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms
US5939602A (en) * 1995-06-06 1999-08-17 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase and inhibitor-resistant mutants thereof
US6023012A (en) * 1996-02-28 2000-02-08 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase
US6084155A (en) 1995-06-06 2000-07-04 Novartis Ag Herbicide-tolerant protoporphyrinogen oxidase ("protox") genes
HUP9900623A3 (en) * 1996-02-28 2001-11-28 Novartis Ag Promoters from plant protoporphyrinogen oxidase genes
JPH10330359A (ja) * 1997-03-31 1998-12-15 Nippon Bayeragrochem Kk フエニルアセチレン誘導体及び除草剤
DE102005017152B4 (de) * 2005-04-13 2007-02-08 Lindauer Dornier Gmbh Verfahren zum Trocknen von vorzugsweise plattenförmigen Produkten und Durchlauftrockner in Mehretagenbauweise
SI2443102T1 (sl) 2009-06-19 2013-08-30 Basf Se Herbicidni benzoksazinoni
US8445407B2 (en) * 2009-11-02 2013-05-21 Basf Se Herbicidal tetrahydrophthalimides
CN103221409B (zh) * 2010-10-01 2016-03-09 巴斯夫欧洲公司 除草的苯并*嗪酮类
US8916501B2 (en) 2010-12-15 2014-12-23 Basf Se Herbicidal compositions
CN102875569A (zh) * 2012-09-27 2013-01-16 南开大学 具有除草活性和抗肝癌活性的异噁唑并嘧啶酮(或三嗪酮)类化合物
AU2017375394B2 (en) * 2016-12-16 2021-10-21 Basf Se Herbicidal phenyltriazolinones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393071A (en) * 1975-03-17 1983-07-12 Naoharu Fujii Method of treating gastric, mammary, lung and uterus tumors
US4404019A (en) * 1980-12-24 1983-09-13 Sumitomo Chemical Company, Limited 3-Chloro-1-phenyl-1,2,4-triazolin-5-ones and their use as herbicides
CH651029A5 (de) * 1980-12-25 1985-08-30 Nihon Nohyaku Co Ltd Triazolin-derivate, verfahren zu ihrer herstellung und sie enthaltende herbizide mittel.
JPS60190711A (ja) * 1984-03-09 1985-09-28 Tokyo Tanabe Co Ltd プロトポルフイリン類注射用製剤
US4755217A (en) * 1987-01-15 1988-07-05 Fmc Corporation Triazinedione herbicides
US4761174A (en) * 1987-04-14 1988-08-02 Fmc Corporation Triazolin-5-one herbicides

Also Published As

Publication number Publication date
LU87949A1 (fr) 1991-12-16
LV10303B (en) 1995-08-20
LV10303A (lv) 1994-10-20
KR930003116B1 (ko) 1993-04-19
PT92546B (pt) 1995-09-12
CH681779A5 (enExample) 1993-05-28
SE9101807D0 (sv) 1991-06-12
EP0447491B1 (en) 1993-08-11
DK110791D0 (da) 1991-06-11
SE505938C2 (sv) 1997-10-27
AR243605A1 (es) 1993-08-31
EG18822A (en) 1994-09-29
AU633537B2 (en) 1993-02-04
CA2004979A1 (en) 1990-06-12
JP2545000B2 (ja) 1996-10-16
JPH04501420A (ja) 1992-03-12
HUT58202A (en) 1992-02-28
WO1990006748A2 (en) 1990-06-28
EP0447491A1 (en) 1991-09-25
DE3991484C2 (de) 1995-02-23
GR890100817A (en) 1991-03-15
KR910700046A (ko) 1991-03-13
NO912228D0 (no) 1991-06-11
MC2171A1 (fr) 1992-05-22
AU4822290A (en) 1990-07-10
BR8907817A (pt) 1991-10-22
IE893925L (en) 1990-06-12
NO912228L (no) 1991-06-11
FI912784A7 (fi) 1991-06-10
ES2051675T1 (es) 1994-07-01
DK110791A (da) 1991-08-12
GB2247404B (en) 1993-03-03
OA09362A (en) 1992-09-15
WO1990006748A3 (en) 1990-10-04
DE3991484T (enExample) 1991-11-21
ATA903489A (de) 1995-06-15
GB2247404A (en) 1992-03-04
AT400520B (de) 1996-01-25
GB9110472D0 (en) 1991-11-27
IE62621B1 (en) 1995-02-22
FI912784A0 (fi) 1991-06-10
PT92546A (pt) 1990-06-29
NZ231658A (en) 1992-05-26
GR1000609B (el) 1992-08-31
SE9101807L (sv) 1991-06-12
IL92622A0 (en) 1990-08-31
ES2051675T3 (es) 1994-11-01

Similar Documents

Publication Publication Date Title
US5407808A (en) Method and composition for photodynamic treatment and detection of tumors
AU633537B2 (en) Use of certain herbicides in cancer treatment and production of protoporphyrin ix
US5298502A (en) Method and composition for photodynamic treatment and detection of tumors
Wang et al. Understanding coenzyme Q
Shukla et al. Glutathione peroxidase and catalase in liver, kidney, testis and brain regions of rats following cadmium exposure and subsequent withdrawal
JPH11507646A (ja) 疾患の予防及び治療のための酸化防止剤として有用な合成触媒遊離基スカベンジャー
US4898878A (en) Antioxidant thiohistidine compounds
Becker et al. [15] 1, 3-Bis (2-chloroethyl)-1-nitrosourea as Thiol-carbamoylating agent in biological Systems
Gibson et al. Relationship of δ-aminolevulinic acid-induced protoporphyrin IX levels to mitochondrial content in neoplastic cells in vitro
Siemann et al. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy
WO1991019418A1 (en) Treatment of disease
Thakar et al. Effect of antitumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions
Mukhopadhyay et al. Vitamin D3 as a modulator of cellular antioxidant defence in murine lymphoma
Scott et al. Metalloporphyrin phototoxicity
RU2074719C1 (ru) Способ разрушения опухолевых клеток млекопитающих и фармацевтическая композиция для разрушения опухолевых клеток млекопитающих
Kessel et al. Porphyrin localizing phenomena
HRP930762A2 (en) Preparation and use of porphyrin
LABBE et al. Clinical-Biochemical Interpretations of Erythrocyte Protoporphyrin¹
Aneja et al. Modulatory influence of tin-protoporphyrin on gossypol-induced alterations of heme oxygenase activity in male wistar rats
LT3997B (en) Process for preparing protoporphyrins and use thereof
EP0450041A1 (en) ORAL PORPHYRINE FOR REGULATING IRON ABSORPTION.
Varior Biochemical and Histopathological effects of aflatoxin on Oreochromis mossambicus (Peters)
Chong Alterations in calcium homeostasis as a possible cause of Ochratoxin A nephrotoxicity
Hall The antimutagenic effects of vitamins C and E on cyclophosphamide
Gill TOXICOLOGICAL STUDIES ON FENVALERATE, NITRATE AND THEIR INTERACTION IN BUFFALO CALVES

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH Patent void